252 related articles for article (PubMed ID: 10472443)
21. Drug resistance in human African trypanosomiasis.
Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
[TBL] [Abstract][Full Text] [Related]
22. Current chemotherapy of human African trypanosomiasis.
Docampo R; Moreno SN
Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
[TBL] [Abstract][Full Text] [Related]
23. Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola.
Robays J; Raguenaud ME; Josenando T; Boelaert M
Trop Med Int Health; 2008 Feb; 13(2):265-71. PubMed ID: 18304274
[TBL] [Abstract][Full Text] [Related]
24. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
Bisser S; N'Siesi FX; Lejon V; Preux PM; Van Nieuwenhove S; Miaka Mia Bilenge C; Būscher P
J Infect Dis; 2007 Feb; 195(3):322-9. PubMed ID: 17205469
[TBL] [Abstract][Full Text] [Related]
25. An alternative form of melarsoprol in sleeping sickness.
Kennedy PG
Trends Parasitol; 2012 Aug; 28(8):307-10. PubMed ID: 22704910
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy against human African trypanosomiasis: is there a road to success?
Burri C
Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy of African trypanosomiasis.
Williamson J
Trop Dis Bull; 1976 Jul; 73(7):531-42. PubMed ID: 135387
[No Abstract] [Full Text] [Related]
28. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo].
Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ
Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda.
Politi C; Carrín G; Evans D; Kuzoe FA; Cattand PD
Health Econ; 1995; 4(4):273-87. PubMed ID: 8528430
[TBL] [Abstract][Full Text] [Related]
30. Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis).
Blum JA; Burri C; Hatz C; Kazumba L; Mangoni P; Zellweger MJ
Trop Med Int Health; 2007 Dec; 12(12):1422-32. PubMed ID: 18076548
[TBL] [Abstract][Full Text] [Related]
31. Treatment of human African trypanosomiasis.
Dumas M; Bouteille B
Bull World Health Organ; 2000; 78(12):1474. PubMed ID: 11196500
[No Abstract] [Full Text] [Related]
32. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
33. Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
Simarro PP; Franco J; Diarra A; Postigo JA; Jannin J
Parasitology; 2012 Jun; 139(7):842-6. PubMed ID: 22309684
[TBL] [Abstract][Full Text] [Related]
34. [In vivo resistance to strains of Trypanosoma rhodesiense, Mozambique, 1985].
Pérez Martín O; Lastre González M; Urban M; Shwalbach J
Rev Cubana Med Trop; 1991; 43(3):189-93. PubMed ID: 9768188
[TBL] [Abstract][Full Text] [Related]
35. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.
Pépin J; Mpia B
Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288
[TBL] [Abstract][Full Text] [Related]
36. Effect of melarsoprol treatment on circulating IL-10 and TNF-alpha levels in human African trypanosomiasis.
Rhind SG; Sabiston BH; Shek PN; Buguet A; Muanga G; Stanghellini A; Dumas M; Radomski MW
Clin Immunol Immunopathol; 1997 May; 83(2):185-9. PubMed ID: 9143380
[TBL] [Abstract][Full Text] [Related]
37. [Three patients with African sleeping sickness following a visit to Tanzania].
Mendonça Melo M; Rasica M; van Thiel PP; Richter C; Kager PA; Wismans PJ
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2552-6. PubMed ID: 12532670
[TBL] [Abstract][Full Text] [Related]
38. [2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993].
Ancelle T; Barret B; Flachet L; Moren A
Bull Soc Pathol Exot; 1994; 87(5):341-6. PubMed ID: 7496198
[TBL] [Abstract][Full Text] [Related]
39. Production of sleeping-sickness treatment.
Pécoul B; Gastellu M
Lancet; 1999 Sep; 354(9182):955-6. PubMed ID: 10489988
[No Abstract] [Full Text] [Related]
40. Melarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the Congo.
Pyana Pati P; Van Reet N; Mumba Ngoyi D; Ngay Lukusa I; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3212. PubMed ID: 25275572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
